<DOC>
	<DOCNO>NCT02169466</DOCNO>
	<brief_summary>To investigate effect three single oral dos BIA 9-1067 ( 25 mg , 50 mg 100 mg ) levodopa pharmacokinetics administer combination single-dose controlled-release levodopa 100 mg/benserazide 25 mg ( Madopar HBS ) .</brief_summary>
	<brief_title>Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses BIA 9-1067 Single-dose Controlled-release 100/25 mg Levodopa/Benserazide</brief_title>
	<detailed_description>Single centre , double-blind , randomize , placebo-controlled , crossover study four consecutive single-dose treatment period . The washout period dose least10 day . On treatment period ( 25 , 50 100 mg BIA 9-1067 placebo ) , completion pre-dose assessment , BIA 9-1067-Placebo administer concomitantly dose Madopar HBS ; post-dose assessment complete subject discharge 72 h post-dose .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Benserazide , levodopa drug combination</mesh_term>
	<criteria>Male subject 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Subjects clinical laboratory test result clinically acceptable screen admission first treatment period . Subjects negative test hepatitis B surface antigen ( HBsAg ) , antihepatitis C antibody ( HCV Ab ) , Human immunodeficiency viruses 1 2 antibody ( HIV1 HIV2 Ab ) screening . Subjects had/were negative drug abuse screen admission treatment period . Subjects nonsmoker smoke ≤10 cigarette equivalent per day . Subjects able willing give write informed consent . Subjects conform inclusion criterion , Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history glaucoma . Subjects history alcoholism drug abuse . Subjects consume 21 unit alcohol week . Subjects significant infection know inflammatory process screen first admission . Subjects acute gastrointestinal symptom time screen first admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use medicine within 2 week first admission , opinion investigator , may affect safety study assessment . Subjects use investigational drug participate clinical trial within 2 month first admission . Subjects donate received blood blood product within previous 2 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . Subjects BIAL Portela &amp; Cª , SA employee .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Parkinson 's disease ( PD )</keyword>
	<keyword>Opicapone</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>